Protease inhibitor monotherapy is effective in controlling human immunodeficiency virus 1 shedding in the male genital tract. (January 2016)

• Record Type: Journal Article
• Authors: Torres-Cornejo, A.; BenMarzouk-Hidalgo, O.J.; Viciana, P.; Sánchez, B.; López-Ruz, M.A.; López-Cortés, L.F.; Gutiérrez-Valencia, A.
• Is Part Of: Clinical microbiology and infection. Volume 22:Number 1(2016)
• Page Start: 98.e7
• Page End: 98.e10
• Publication Date: 2016-01
• Subjects: Human immunodeficiency virus 1 infection -- human immunodeficiency virus 1 treatment -- male genital tract -- protease inhibitor monotherapy -- triple therapy; Medical microbiology -- Periodicals; Diagnostic microbiology -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 616.01
• DOI: 10.1016/j.cmi.2015.09.028
• Languages: English
• ISSNs: 1198-743X

Abstract

Abstract: Cross-sectional study comparing seminal human immunodeficiency virus type 1 (HIV-1) shedding in patients receiving boosted protease inhibitor monotherapy (mtPI/rtv) ( n = 66) versus triple therapy (TT) ( n = 61). Seminal HIV-1 shedding rates in patients with undetectable plasma HIV-RNA were 16.0% on mtPI/rtv compared with 28.6% on TT (p 0.173). Aviraemic status and time on viral suppression were independently associated with lack of seminal HIV-1 shedding. During TT, non PI/rtv-based regimens were associated with a better control of HIV infection in semen despite similar time on viral suppression. The use of mtPI/rtv in well-controlled patients is not associated with increased seminal HIV excretion compared with TT.